FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD. Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting. In this episode, we discuss: The FDA advisory committee process and its implications for drug approvalsFunctional unblinding and expectancy effects in psychedelic c...